W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza IV
MRD registry and multicenter, randomized controlled pragmatic trial of standard intensity versus reduced intensity consolidation treatment in MRD-negative patients with AML or…
Miasta: Gdańsk, Gliwice, Katowice, Kraków i 4 inne miastaWiek: od 18 latSponsor: Medizinische Hochschule Hannover
RekrutujeFaza III
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Miasta: Gdańsk, Legnica, Olsztyn, Warszawa i 1 inne miastoWiek: od 18 latSponsor: Ascentage Pharma Group Inc.
RekrutujeFaza III
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Miasta: Katowice, Olsztyn, Poznań, Wrocław i 1 inne miastoWiek: od 18 latSponsor: Takeda Development Center Americas Inc.
RekrutujeFaza III
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Miasta: Gdynia, Lublin, ŁódźWiek: od 18 latSponsor: Taiho Oncology Inc.